Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?

Therapeutic management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is challenging. The mammalian target of rapamycin (mTOR) inhibitor everolimus recently obtained approval from the Food and Drug Administration for the treatment of patients with advanced pancreatic neuroendocrine tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Amira, Romano, David, Saveanu, Alexandru, Roche, Catherine, Albertelli, Manuela, Barbieri, Federica, Brue, Thierry, Niccoli, Patricia, Delpero, Jean-Robert, Garcia, Stephane, Ferone, Diego, Florio, Tullio, Moutardier, Vincent, Poizat, Flora, Barlier, Anne, Gerard, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522327/
https://www.ncbi.nlm.nih.gov/pubmed/28454119
http://dx.doi.org/10.18632/oncotarget.17008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522327/
https://www.ncbi.nlm.nih.gov/pubmed/28454119
http://dx.doi.org/10.18632/oncotarget.17008

Ejemplares similares